Boothbay Fund Management’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

Boothbay Fund Management’s Portfolio XPH Stock Details XPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-4,728	Closed	-$242K	–	566
2015 Q4	$242K	Buy	+4,728	New	+$241K	0.11%	346

Other funds holding XPH

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

PVH

Psagot Value Holdings Tel Aviv, Israel $11M AUM 32.09% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Baird Financial Group Milwaukee, Wisconsin $64B AUM 22.64% 1-Year Est. Return

KHLMVGHM

Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet Tel Aviv, Israel $1.53B AUM 20.88% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

Boothbay Fund Management's XPH Position: Q1 2016 in Review

Boothbay Fund Management sold out of State Street SPDR S&P Pharmaceuticals ETF (XPH) in Q1 2016, closing a stake of 4,728 shares — an estimated $242K sold.

Boothbay Fund Management first reported a position in XPH in Q4 2015 and held it in 1 quarter. The position peaked at $242K in Q4 2015. 71 funds tracked by Wall St. Rank hold XPH as of Q1 2016.

Boothbay Fund Management reported no remaining State Street SPDR S&P Pharmaceuticals ETF position as of Q1 2016 after selling out during the quarter.
Boothbay Fund Management sold 4,728 State Street SPDR S&P Pharmaceuticals ETF shares in Q1 2016, an estimated $242K.
Boothbay Fund Management first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q4 2015 and held it in 1 quarter.
Boothbay Fund Management's State Street SPDR S&P Pharmaceuticals ETF position peaked at $242K in Q4 2015.
71 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q1 2016.

Based on Boothbay Fund Management's 13F filing for Q1 2016, filed 16 May 2016.